HAS2 and breast cancer: Kaplan–Meier survival analysis of breast cancer patients (n = 148) demonstrated co-expression of GFAT and HAS2 to be more significantly associated with worse overall patient survival than the respective expression of GFAT or HAS2 alone (Fig. 1b).